Table 2.
Targeted therapy of psoriasis
| Target | Molecule | Types of psoriasis | Drug dose | Efficacy | PMID | |
|---|---|---|---|---|---|---|
| TNFα | Etanercept | plaque psoriasis | 50 mg twice weekly | PASI 75 | 49.0% at week 12 | 14627786 |
| 59.0% at week 24 | ||||||
| 47.0% at week 12 | 16399150 | |||||
| psoriatic arthritis | 50 mg once weekly | ACR 20 | 60.8% at week 12 | 20124563 | ||
| 71.7% at week 24 | ||||||
| 50 mg twice weekly | ACR 20 | 66.4% at week 12 | ||||
| 69.0% at week 24 | ||||||
| Infliximab | plaque psoriasis | week 0, 2, and 6, then every 8 week to week 46 | PASI 75 |
80.0% at week 10 82.0% at week 24 |
16226614 | |
| PASI 90 |
57.0% at week 10 58.0% at week 24 |
|||||
| 5 mg/kg at week 0, 2, 6, 14 and 22 | PASI 75 | 72.0% at week 24 | 27416891 | |||
| 67.0% at week 48 | ||||||
| psoriatic arthritis | 5 mg/kg at week 0, 2, 6, 14 and 22 | ACR 20 | 58.0% at week 14 | 15677701 | ||
| Adalimumab | plaque psoriasis |
80 mg at week 0; 40 mg until week 16 twice weekly |
PASI 75 | 71.0% at week 16 | 17936411 | |
| 40 mg once weekly | PASI 75 | 80.0% at week 12 | 17010738 | |||
| 40 mg twice weekly | PASI 75 | 53.0% at week 12 | ||||
| psoriatic arthritis | 40 mg twice weekly | ACR 20 | 74.0% at week 12 | 19815494 | ||
| ACR 50 | 51.0% at week 12 | |||||
| ACR 70 | 32.0% at week 12 | |||||
| nail psoriasis |
80 mg at week 0; 40 mg until week 16 twice weekly |
NAPSI 75 | 46.6% at week 26 | 28993005 | ||
| IL-17A | secukinumab | plaque psoriasis | 150 mg (administered once weekly for 5 week, then every 4 week), | PASI 75 |
71.6% at week 12 67.0% at week 12 |
25007392 |
| PASI 90 |
39.1% at week 12 41.9% at week 12 |
|||||
| 300 mg (administered once weekly for 5 weeks, then every 4 week), | PASI 75 |
81.6% at week 12 77.1% at week 12 |
||||
| PASI 90 |
59.2% at week 12 54.2% at week 12 |
|||||
| psoriatic arthritis | 150 mg (once a week from baseline and then every 4 week from week 4) | ACR 20 | 51.0% at week 24 | 26135703 | ||
| ACR 50 | 35.0% at week 24 | |||||
| 300 mg (once a week from baseline and then every 4 week from week 4) | ACR 20 | 54.0% at week 24 | ||||
| ACR 50 | 35.0% at week 24 | |||||
| nail psoriasis | 150 mg (once a week from baseline and then every 4 week from week 4) | NAPSI |
37.9% at week 16 52.6% at week 32 |
30367462 | ||
| 300 mg (once a week from baseline and then every 4 week from week 4) | NAPSI |
45.3% at week 16 63.2% at week 32 |
||||
| Ixekizumab | plaque psoriasis | 160 mg at week 0, and then 80 mg twice weekly | PSAI 75 |
89.1% at week 12 87.0% at week 12 |
27299809 | |
| PSAI 90 |
70.9% at week 12 68.0% at week 12 |
|||||
| PSAI 100 |
35.3% at week 12 38.0% at week 12 |
|||||
| 160 mg at week 0, and then 80 mg every four weekly | PSAI 75 |
82.6% at week 12 84.0% at week 12 |
||||
| PSAI 90 |
64.6% at week 12 65.0% at week 12 |
|||||
| PSAI 100 |
33.6% at week 12 35.0% at week 12 |
|||||
| psoriatic arthritis | 160 mg at week 0, and then 80 mg twice weekly | ACR 20 | 48.0% at week 24 | 28551073 | ||
| ACR 50 | 33.0% at week 24 | |||||
| ACR 70 | 12.0% at week 24 | |||||
| 160 mg at week 0, and then 80 mg every four weekly | ACR 20 | 53.0% at week 24 | ||||
| ACR 50 | 35.0% at week 24 | |||||
| ACR 70 | 22.0% at week 24 | |||||
| nail psoriasis | 160 mg at week 0, and then 80 mg twice weekly | NAPSI | 35.2% at week 12 | 27910156 | ||
| NAPSI 0 | 17.5% at week 12 | |||||
| 160 mg at week 0, and then 80 mg every four weekly | NAPSI | 36.7% at week 12 | ||||
| NAPSI 0 | 19.7% at week 12 | |||||
| IL-17F and IL-17A | Bimekizumab | plaque psoriasis | 320 mg every 4 week | PSAI 75 |
95.4% at week 16 93.3% at week 16a |
33549192 33891380a |
| PSAI 90 |
90.8% at week 16 85.5% at week 16a |
|||||
| PSAI 100 |
68.2% at week 16 61.7% at week 16a |
|||||
| psoriatic arthritis | 160 mg every 4 week | ACR 20 |
67.0% at week 16 62.0% at week 16a 65.0% at week 24a |
36495881 36493791a |
||
| ACR 50 |
43.4% at week 16 44.0% at week 16a 45.0% at week 24a |
|||||
| ACR 70 |
26.6% at week 16 24.0% at week 16a 29.0% at week 24a |
|||||
| IL-17 receptor | Brodalumab | plaque psoriasis | 210 mg at week 0,1,2,4,6,8,10 | PASI 75 |
86.0% at week 12 85.0% at week 12 |
26422722 |
| PASI 100 |
44.0% at week 12 37.0% at week 12 |
|||||
| 140 mg at week 0,1,2,4,6,8,10 | PASI 75 |
67.0% at week 12 69.0% at week 12 |
||||
| PASI 100 |
26.0% at week 12 27.0% at week 12 |
|||||
| psoriatic arthritis | 280 mg at week 0,1,2,4,6,8,10 | ACR 20 | 39.0% at week 12 | 24918373 | ||
| ACR 50 | 14.0% at week 12 | |||||
| ACR 70 | 5.0% at week 12 | |||||
| 140 mg at week 0,1,2,4,6,8,10 | ACR 20 | 37.0% at week 12 | ||||
| ACR 50 | 14.0% at week 12 | |||||
| ACR 70 | 5.0% at week 12 | |||||
| 210 mg twice weekly | ACR 20 |
51.8% at week 16 44.3% at week 16 |
33106286 | |||
| ACR 50 |
28.8% at week 16 23.2% at week 16 |
|||||
| ACR 70 |
12.5% at week 16 10.2% at week 16 |
|||||
| 140 mg twice weekly | ACR 20 |
39.5% at week 16 50.9% at week 16 |
||||
| ACR 50 |
18.3% at week 16 9.3% at week 16 |
|||||
| ACR 70 |
7.8% at week 16 13.3% at week 16 |
|||||
| IL12/IL23 p40 | Ustekinumab | plaque psoriasis | 45 mg (at week 0 and 4 and then every 12 week) | PASI 75 |
67.1% at week 12 66.7% at week 12a 71.2% at week 28 69.5% at week 28a |
18486739 18486740a |
| PASI 90 |
41.6% at week 12 42.3% at week 12a 49.2% at week 28 44.8% at week 28a |
|||||
| PASI 100 |
12.5% at week 12 18.1% at week 12a 20.8% at week 28 18.6% at week 28a |
|||||
| 90 mg (at week 0 and 4 and then every 12 week) | PASI 75 |
66.4% at week 12 75.7% at week 12a 78.6% at week 28 78.5% at week 28a |
||||
| PASI 90 |
36.7% at week 12 50.9% at week 12a 44.7% at week 28 54.3% at week 28a |
|||||
| PASI 100 |
10.9% at week 12 18.2% at week 12a 29.2% at week 28 29.5% at week 28a |
|||||
| psoriatic arthritis | 45 mg (at week 0 and 4 and then every 12 week) | ACR 20 | 42.4% at week 24 | 23769296 | ||
| 90 mg (at week 0 and 4 and then every 12 week) | ACR 20 | 49.5% at week 24 | ||||
| nail psoriasis | 45 or 90 mg, according to body weight, at week 0, 4, and 16 | NAPSI |
46.5% at week 24 (45 mg) 48.7% at week 24 (90 mg) |
24117389 | ||
| IL-23 p19 | Guselkumab | plaque psoriasis | 100 mg at week 0 and 4 then every 8 weeks | PASI 75 | 89.0% at week 12 | 31402114 |
| PASI 90 |
69.0% at week 12 76.3% at week 48 |
|||||
| PASI 100 | 58.0% at week 48 | |||||
| psoriatic arthritis | 100 mg at week 0, 4, then every 4 weeks | ACR 20 | 59.0% at week 24 | 32178765 | ||
| 100 mg at week 0, 4, then every 8 weeks | ACR 20 | 52.0% at week 24 | ||||
| Tildrakizumab | plaque psoriasis | 100 mg at week 0, 4, 12, 16 | PASI 75 |
64.0% at week 12 61.0% at week 12 80.0% at week 28 |
28596043 | |
| PASI 90 |
35.0% at week 12 39.0% at week 12 52.0% at week 28 |
|||||
| PASI 100 |
14.0% at week 12 12.0% at week 12 24.0% at week 28 |
|||||
| 200 mg at week 0, 4, 12, 16 | PASI 75 |
62.0% at week 12 66.0% at week 12 82.0% at week 28 |
||||
| PASI 90 |
35.0% at week 12 37.0% at week 12 59.0% at week 28 |
|||||
| PASI 100 |
14.0% at week 12 12.0% at week 12 32.0% at week 28 |
|||||
| Risankizumab | plaque psoriasis | 150 mg at week 0, 4, 16, 28, and 40 | PASI 90 |
75.3% at week 16 74.8% at week 16 81.9% at week 52 80.6% at week 52 |
30097359 | |
| PASI 100 |
35.9% at week 16 50.7% at week 16 56.3% at week 52 59.5% at week 52 |
|||||
| IL-36 receptor | Spesolimab | Generalized pustular psoriasis | a single intravenous dose of 900 mg | GPPGA 0 | 54% at week 1 | 34936739 |
| JAK1, JAK3 | Tofacitinib | psoriatic arthritis | 5 mg twice daily | ACR 20 |
54.0% at month 3 73.0% at month 12 |
29045212 |
| ACR 50 |
30.0% at month 3 48.0% at month 12 |
|||||
| 10 mg twice daily | ACR 20 |
63.0% at month 3 73.0% at month 12 |
||||
| ACR 50 |
42.0% at month 3 50.0% at month 12 |
|||||
| JAK1 | Upadacitinib | psoriatic arthritis | 15 mg once daily | ACR 20 |
70.6% at week 12 56.9% at week 12a 73.4% at week 24 |
33789011 33272960a |
| ACR 50 |
37.5% at week 12 52.4% at week 24 |
|||||
| ACR 70 |
15.6% at week 12 28.7% at week 24 |
|||||
| 30 mg once daily | ACR 20 |
78.5% at week 12 63.8% at week 12a 78.5% at week 24 |
||||
| ACR 50 |
51.8% at week 12 60.5% at week 24 |
|||||
| ACR 70 |
25.3% at week 12 36.4% at week 24 |
|||||
| TYK2 | Deucravacitinib | plaque psoriasis | 6 mg once daily | PSAI 75 |
58.4% at week 12 69.3% at week 24 |
35820547 |
| PSAI 90 |
35.5% at week 12 42.2% at week 24 |
|||||
| PSAI 100 |
14.2% at week 12 17.5% at week 24 |
|||||
| PDE4 | Apremilast | plaque psoriasis | 30 mg twice a day | PSAI 75 | 33.1% at week 16 | 26089047 |
| PSAI 90 | 9.8% at week 16 | |||||
| psoriatic arthritis | ACR 20 | 40.0% at week 16 | 24595547 | |||
| roflumilast | plaque psoriasis | Cream for once daily | IGA success |
37.5% at week 8 42.4% at week 8 |
36125472 | |
PASI 75: the proportion of patients who had a reduction by ≥75% in Psoriasis Area and Severity Index; PASI 90: the proportion of patients who had a reduction by ≥90% in Psoriasis Area and Severity Index; PASI 100: the proportion of patients who had a 100% reduction in Psoriasis Area and Severity Index
ACR 20: the proportion of patients who had a ≥ 20% improvement according to the American College of Rheumatology criteria; ACR 50: the proportion of patients who had a ≥ 50% improvement according to the American College of Rheumatology criteria; ACR 70: the proportion of patients who had a ≥ 70% improvement according to the American College of Rheumatology criteria
NAPSI 75: the proportion of patients who had ≥75% improvement in total-fingernail modified Nail Psoriasis Severity Index (NAPSI75)
NAPSI: Nail Psoriasis Severity Index
NAPSI 0: the proportion of patients who achieved a NAPSI score of 0
IGA success: Investigator Global Assessment (IGA) is clear or almost clear status plus ≥2-grade improvement from baseline [score range, 0–4]
GPPGA 0: the proportion of patients who scored 0 on the Generalized Pustular Psoriasis Physician Global Assessment pustulation subscale
aThe results regarding efficacy were obtained from the PMID literature with the samea for the same molecule